Status: Recruiting
Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors
This is a first in human, multi-center, open-label, dosage escalation study to determine the recommended dose range of TH9619 in subjects with advanced cancer.
Participants needed: 43
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: One-carbon Therapeutics ABUpdated: Jan 28, 2026Locations: 4
Eligibility criteria
Must have given written informed consent [+4]